CN102576016A - Sparc微环境标签在癌症治疗中的应用 - Google Patents
Sparc微环境标签在癌症治疗中的应用 Download PDFInfo
- Publication number
- CN102576016A CN102576016A CN201080047076XA CN201080047076A CN102576016A CN 102576016 A CN102576016 A CN 102576016A CN 201080047076X A CN201080047076X A CN 201080047076XA CN 201080047076 A CN201080047076 A CN 201080047076A CN 102576016 A CN102576016 A CN 102576016A
- Authority
- CN
- China
- Prior art keywords
- tumour
- tumor
- sparc
- sms
- neoplasm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Nanotechnology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27696909P | 2009-09-18 | 2009-09-18 | |
| US61/276,969 | 2009-09-18 | ||
| PCT/US2010/049545 WO2011035274A1 (en) | 2009-09-18 | 2010-09-20 | Use of the sparc microenvironment signature in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102576016A true CN102576016A (zh) | 2012-07-11 |
Family
ID=43759058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201080047076XA Pending CN102576016A (zh) | 2009-09-18 | 2010-09-20 | Sparc微环境标签在癌症治疗中的应用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20120245089A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2478362B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2013505268A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20120092597A (cg-RX-API-DMAC7.html) |
| CN (1) | CN102576016A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2010295324B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112012008316A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2774550A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL218642A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2012003287A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ598801A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011035274A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201202657B (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8383358B2 (en) * | 2009-05-28 | 2013-02-26 | Abraxis Bioscience, Llc | Use of 2 anti-SPARC antibodies to predict response to melanoma chemotherapy |
| AU2011261240A1 (en) * | 2010-06-03 | 2013-01-10 | Abraxis Bioscience, Llc | Use of the SPARC microenvironment signature in the treatment of cancer |
| EP3539080B1 (en) * | 2016-11-10 | 2022-03-23 | F. Hoffmann-La Roche AG | Distance-based tumor classification |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006043362A1 (ja) * | 2004-10-19 | 2006-04-27 | Kumamoto University | 悪性黒色腫(メラノーマ)の新規な診断キット |
| CN1867679A (zh) * | 2003-07-17 | 2006-11-22 | 环太平洋生物技术有限公司 | 用于胃癌检测的标记物 |
| CN1922332A (zh) * | 2003-12-31 | 2007-02-28 | 宾夕法尼亚州研究基金会 | 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法 |
| CN101014720A (zh) * | 2004-08-10 | 2007-08-08 | 加的夫大学学院咨询有限公司 | 用于乳腺癌的预后的方法和试剂盒 |
| CN101160321A (zh) * | 2005-02-18 | 2008-04-09 | 阿布拉西斯生物科学公司 | Q3 sparc缺失突变体及其用途 |
| AU2008226283A1 (en) * | 2007-03-09 | 2008-09-18 | The University Of British Columbia | Assessing chemotherapy resistance of colorectal tumors by determining sparc hypermethylation |
| WO2008128169A1 (en) * | 2007-04-13 | 2008-10-23 | Abraxis Bioscience, Inc. | Sparc and methods of use thereof |
| CN101454673A (zh) * | 2006-03-31 | 2009-06-10 | 阿布拉西斯生物科学公司 | Sparc及其使用方法 |
| CN101472943A (zh) * | 2006-06-16 | 2009-07-01 | 国立大学法人熊本大学 | 来自sparc的癌排斥抗原肽以及含有该肽的药物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5003621A (en) | 1989-11-02 | 1991-03-26 | Motorola, Inc. | Direct conversion FM receiver |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| WO2004085621A2 (en) * | 2003-03-20 | 2004-10-07 | Dana-Farber Cancer Institute, Inc. | Gene expression in breast cancer |
| CN103169729A (zh) * | 2005-02-18 | 2013-06-26 | 阿布拉科斯生物科学有限公司 | 治疗剂的组合和给予方式以及联合治疗 |
| US9675578B2 (en) * | 2006-12-14 | 2017-06-13 | Abraxis Bioscience, Llc | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| AU2008260447B2 (en) * | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
-
2010
- 2010-09-20 JP JP2012529971A patent/JP2013505268A/ja active Pending
- 2010-09-20 EP EP10817999.5A patent/EP2478362B1/en active Active
- 2010-09-20 BR BR112012008316A patent/BR112012008316A2/pt not_active IP Right Cessation
- 2010-09-20 CN CN201080047076XA patent/CN102576016A/zh active Pending
- 2010-09-20 NZ NZ598801A patent/NZ598801A/en not_active IP Right Cessation
- 2010-09-20 WO PCT/US2010/049545 patent/WO2011035274A1/en not_active Ceased
- 2010-09-20 US US13/496,385 patent/US20120245089A1/en not_active Abandoned
- 2010-09-20 CA CA2774550A patent/CA2774550A1/en not_active Abandoned
- 2010-09-20 MX MX2012003287A patent/MX2012003287A/es not_active Application Discontinuation
- 2010-09-20 AU AU2010295324A patent/AU2010295324B2/en not_active Ceased
- 2010-09-20 KR KR1020127009670A patent/KR20120092597A/ko not_active Withdrawn
-
2012
- 2012-03-14 IL IL218642A patent/IL218642A0/en unknown
- 2012-04-12 ZA ZA2012/02657A patent/ZA201202657B/en unknown
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1867679A (zh) * | 2003-07-17 | 2006-11-22 | 环太平洋生物技术有限公司 | 用于胃癌检测的标记物 |
| CN1922332A (zh) * | 2003-12-31 | 2007-02-28 | 宾夕法尼亚州研究基金会 | 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法 |
| CN101014720A (zh) * | 2004-08-10 | 2007-08-08 | 加的夫大学学院咨询有限公司 | 用于乳腺癌的预后的方法和试剂盒 |
| WO2006043362A1 (ja) * | 2004-10-19 | 2006-04-27 | Kumamoto University | 悪性黒色腫(メラノーマ)の新規な診断キット |
| CN101160321A (zh) * | 2005-02-18 | 2008-04-09 | 阿布拉西斯生物科学公司 | Q3 sparc缺失突变体及其用途 |
| CN101454673A (zh) * | 2006-03-31 | 2009-06-10 | 阿布拉西斯生物科学公司 | Sparc及其使用方法 |
| CN101472943A (zh) * | 2006-06-16 | 2009-07-01 | 国立大学法人熊本大学 | 来自sparc的癌排斥抗原肽以及含有该肽的药物 |
| AU2008226283A1 (en) * | 2007-03-09 | 2008-09-18 | The University Of British Columbia | Assessing chemotherapy resistance of colorectal tumors by determining sparc hypermethylation |
| WO2008128169A1 (en) * | 2007-04-13 | 2008-10-23 | Abraxis Bioscience, Inc. | Sparc and methods of use thereof |
Non-Patent Citations (5)
| Title |
|---|
| ANDREW H BECK ET AL.: "The fibromatosis signature defines a robust stromalresponse in breast carcinoma", 《ABORATORY INVESTIGATION》, vol. 88, 14 April 2008 (2008-04-14) * |
| DANIELA MASS ET AL.: "Osteonectin Expression Correlates With Clinical Outcome in Thin Cutaneous Malignant Melanomas", 《HUMAN PATHOLOG》, vol. 30, no. 3, 31 March 1999 (1999-03-31), XP008097964, DOI: doi:10.1016/S0046-8177(99)90014-X * |
| GARETH WATKINS ET AL.: "Increased levels of SPARC (osteonectin) in human breast cancertissues and its association with clinical outcomes", 《PROSTAGLANDINS, LEUKOTRIENES AND ESSENTIAL FATTY ACIDS》, vol. 72, 30 April 2005 (2005-04-30), XP004780199, DOI: doi:10.1016/j.plefa.2004.12.003 * |
| JEFFREY R. INFANTE ET AL: "Peritumoral Fibroblast SPARC Expression and Patient OutcomeWith Resectable Pancreatic Adenocarcinoma", 《JOURNAL OF CLINICAL ONCOLOGY》, vol. 25, no. 3, 20 January 2007 (2007-01-20), XP008148514, DOI: doi:10.1200/JCO.2006.07.8824 * |
| NORIHIRO SATO ET AL.: "SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor–stromal interactions", 《ONCOGENE》, vol. 22, 7 August 2003 (2003-08-07), XP002394202, DOI: doi:10.1038/sj.onc.1206807 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010295324A1 (en) | 2012-04-05 |
| US20120245089A1 (en) | 2012-09-27 |
| BR112012008316A2 (pt) | 2017-06-06 |
| WO2011035274A1 (en) | 2011-03-24 |
| IL218642A0 (en) | 2012-05-31 |
| AU2010295324B2 (en) | 2015-04-30 |
| JP2013505268A (ja) | 2013-02-14 |
| MX2012003287A (es) | 2012-08-03 |
| EP2478362B1 (en) | 2016-05-11 |
| ZA201202657B (en) | 2013-09-25 |
| EP2478362A1 (en) | 2012-07-25 |
| NZ598801A (en) | 2014-07-25 |
| CA2774550A1 (en) | 2011-03-24 |
| EP2478362A4 (en) | 2013-09-11 |
| KR20120092597A (ko) | 2012-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20130281376A1 (en) | Sparc microenvironment signature, plasma sparc, and ldh as prognostic biomarkers in the treatment of cancer | |
| US9193782B2 (en) | Use of the SPARC microenvironment signature in the treatment of cancer | |
| US20140005059A1 (en) | Biomarkers for cancer | |
| US9091697B2 (en) | Use of 2 anti-SPARC antibodies to predict response to chemotherapy for pancreatic adenocarcinoma | |
| AU2010295324B2 (en) | Use of the SPARC microenvironment signature in the treatment of cancer | |
| HK1172689A (en) | Use of the sparc microenvironment signature in teh treatment of cancer | |
| HK1170809B (en) | Use of 2 anti-sparc antibodies to predict response to chemotherapy | |
| VAN DAM | FOLATE RECEPTOR-ALPHA AND THE EFFECT OF CHEMOTHERAPY ON EXPRESSION RATES IN OVARIAN CANCER |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120711 |